BR112022021511A2 - Composição de pó seco para administração peroral - Google Patents

Composição de pó seco para administração peroral

Info

Publication number
BR112022021511A2
BR112022021511A2 BR112022021511A BR112022021511A BR112022021511A2 BR 112022021511 A2 BR112022021511 A2 BR 112022021511A2 BR 112022021511 A BR112022021511 A BR 112022021511A BR 112022021511 A BR112022021511 A BR 112022021511A BR 112022021511 A2 BR112022021511 A2 BR 112022021511A2
Authority
BR
Brazil
Prior art keywords
average diameter
weight
volume
dry powder
composition
Prior art date
Application number
BR112022021511A
Other languages
English (en)
Inventor
Camber Ola
Everaert Arnout
Grudén Stefan
Original Assignee
Vicore Pharma Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vicore Pharma Ab filed Critical Vicore Pharma Ab
Publication of BR112022021511A2 publication Critical patent/BR112022021511A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

COMPOSIÇÃO DE PÓ SECO PARA ADMINISTRAÇÃO PERORAL. De acordo com a invenção é fornecida uma forma de dosagem farmacêutica adequada para administração oral no trato gastrointestinal, em que a forma de dosagem compreende uma composição farmacêutica na forma de uma mistura particulada que compreende partículas sólidas de N butiloxicarbonil 3 (4 imidazol 1 ilmetilfenil) 5 iso butiltiofeno 2 sulfonamida (C21), ou um sal farmaceuticamente aceitável do mesmo, misturado por adição com uma mescla de partículas carreadoras com um diâmetro médio baseado em peso e/ou volume, e/ou uma densidade estrutural/de partículas, que é/são semelhantes ao diâmetro médio baseado em peso e/ou volume, e/ou a densidade estrutural/de partículas, das partículas sólidas de C21 e um deslizante, em que a composição está contida dentro de uma cápsula que é adequada para tal administração oral. As partículas carreadoras preferidas têm um diâmetro médio baseado em peso e/ou volume que é inferior a cerca de 100 pm. Os materiais de partículas carreadoras preferidos incluem manitol. Os deslizantes preferidos compreendem sílica coloidal. Tais formas de dosagem encontram utilidade no tratamento de doenças pulmonares, tais como fibrose pulmonar idiopática, sarcoidose e danos nos tecidos induzidos por vírus respiratórios.
BR112022021511A 2020-04-24 2021-04-23 Composição de pó seco para administração peroral BR112022021511A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2006079.4A GB202006079D0 (en) 2020-04-24 2020-04-24 New composition
PCT/GB2021/050994 WO2021214488A1 (en) 2020-04-24 2021-04-23 New dry powder composition for peroral administration

Publications (1)

Publication Number Publication Date
BR112022021511A2 true BR112022021511A2 (pt) 2023-01-24

Family

ID=71080269

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022021511A BR112022021511A2 (pt) 2020-04-24 2021-04-23 Composição de pó seco para administração peroral

Country Status (17)

Country Link
US (1) US11844868B2 (pt)
EP (2) EP4389212A2 (pt)
JP (2) JP7387903B2 (pt)
KR (1) KR20230005220A (pt)
CN (1) CN115697309A (pt)
AU (1) AU2021260923A1 (pt)
BR (1) BR112022021511A2 (pt)
CA (1) CA3180646A1 (pt)
DK (1) DK4138790T3 (pt)
GB (1) GB202006079D0 (pt)
IL (1) IL297373A (pt)
LT (1) LT4138790T (pt)
MX (1) MX2022013070A (pt)
PL (1) PL4138790T3 (pt)
PT (1) PT4138790T (pt)
SI (1) SI4138790T1 (pt)
WO (1) WO2021214488A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202201723D0 (en) 2022-02-10 2022-03-30 Vicore Pharma Ab New use

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9800550D0 (sv) 1998-02-24 1998-02-24 A & Science Invest Ab A pharmaceutical preparation comprising an angiotensin II type 2 receptor agonist, and use thereof
AU2002257970B2 (en) 2001-05-31 2007-08-02 Vicore Pharma Ab Tricyclic compounds useful as angiotensin II agonists
JP2008502699A (ja) 2004-06-14 2008-01-31 セプラコール・インコーポレイテッド 肺疾患治療方法、及びそのための組成物
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
WO2008073927A1 (en) * 2006-12-12 2008-06-19 Gilead Colorado, Inc. Ambrisentan combined with a renin inhibitor for hypertensive disorder
AU2012206945B2 (en) * 2011-01-11 2015-02-19 Dimerix Bioscience Pty Ltd Combination therapy
MX2017010993A (es) * 2015-03-02 2018-04-11 Vicore Pharma Ab Agonista del receptor de angiotensina ii para tratar la fibrosis pulmonar.
WO2017221012A1 (en) 2016-06-21 2017-12-28 Vicore Pharma Ab Methods and compositions for preventing or reducing the risk of cancer treatment-related cardiotoxicity
GB201710906D0 (en) 2017-07-06 2017-08-23 Vicore Pharma Ab Compounds and methods for treating peripheral neuropathy
US11931341B2 (en) * 2018-03-22 2024-03-19 University Of Lowa Research Foundation Compositions and methods for the treatment and prevention of muscular dystrophy
GB201818164D0 (en) 2018-11-07 2018-12-19 Vicore Pharma Ab New composition

Also Published As

Publication number Publication date
PT4138790T (pt) 2024-04-01
AU2021260923A1 (en) 2022-12-08
US11844868B2 (en) 2023-12-19
SI4138790T1 (sl) 2024-05-31
IL297373A (en) 2022-12-01
EP4138790A1 (en) 2023-03-01
JP7387903B2 (ja) 2023-11-28
US20220202726A1 (en) 2022-06-30
KR20230005220A (ko) 2023-01-09
JP2023503178A (ja) 2023-01-26
WO2021214488A1 (en) 2021-10-28
CA3180646A1 (en) 2021-10-28
DK4138790T3 (en) 2024-03-11
LT4138790T (lt) 2024-04-10
GB202006079D0 (en) 2020-06-10
CN115697309A (zh) 2023-02-03
JP2024020417A (ja) 2024-02-14
EP4138790B1 (en) 2024-01-31
MX2022013070A (es) 2022-11-30
PL4138790T3 (pl) 2024-06-10
EP4389212A2 (en) 2024-06-26

Similar Documents

Publication Publication Date Title
ES2754388T3 (es) Composiciones y métodos de dicetopiperazina microcristalina
BR112015021814A2 (pt) aglomerados respiráveis de partículas carreadoras porosas e fármaco micronizado
KR102058097B1 (ko) 다루나비어 복합 제제
BR112015028644A2 (pt) composições de cenicriviroc e métodos de criação e uso do mesmo
BR112013019540A2 (pt) formulações de pó seco de partículas que contêm dois ou mais ingredientes ativos para o tratamento de doenças obstrutivas ou inflamatórias das vias aéreas
HUP0203728A2 (hu) Formoterolt tartalmazó aeroszolkészítmény
TW200916103A (en) Therapeutic compositions and methods
CN110403922A (zh) 通过吸入罗氟司特n-氧化物治疗自身免疫、呼吸和/或炎性病症的方法
ES2598823T3 (es) Formulaciones de darunavir
PT1545634E (pt) Método para preparar composições de pó seco para inalação
CN103025318B (zh) 含有喹啉酮衍生物、和硅油和/或硅油衍生物的悬浮液和块状组合物
JP2004518653A (ja) 不安障害を治療する方法
PT2345426E (pt) Composto orgânico compósito em pó para utilização médica, método de produção do mesmo e suspensão do mesmo
BR112022021511A2 (pt) Composição de pó seco para administração peroral
ES2965017T3 (es) Micropartículas que comprenden un compuesto que contiene azufre
JPWO2009157214A1 (ja) 球状非結晶ケイ酸アルミン酸マグネシウム
WO2017028660A1 (zh) 一种含有喹啉衍生物或其盐的药物组合物
BR112022021520A2 (pt) Composição de liberação atrasada para administração peroral
JP2017122056A (ja) 医薬含有造粒物の製造方法
JPH0713014B2 (ja) 医薬組成物
BR112015020443A8 (pt) formulação em pó para inalação, seus usos e seu processo de preparação, e composição farmacêutica
UA82268C2 (uk) Гранули, що містять гідрохлорид венлафаксину, та спосіб їх виготовлення
MX2017004476A (es) Composicion que comprende al menos un polvo seco obtenido por secado por atomizacion para aumentar la estabilidad de la formulacion.
ES2745983T3 (es) Formas de dosificación farmacéutica
RU2013141446A (ru) Фармацевтическая композиция, содержащая тадалафил и циклодекстрин